Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of ZF874 in Healthy Volunteers and PiXZ Subjects
NCT04443192Phase 1Terminated
- Sponsor
- Z Factor
- Start
- Aug 2020
- Primary completion
- Sep 2022
- Modality
- Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ZF874 in alpha-1 antitrypsin deficiency (AATD) (13 arms), sponsored by Z Factor. Primary endpoint: Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment. Started Aug 2020; status: terminated.
02
Drugs
ZF874
03
Conditions
alpha-1 antitrypsin deficiency (AATD)
Beyond the preview
Go deeper on NCT04443192.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04443192.